Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.
Biomarker and diagnostic research for aggressive NK-cell leukemia has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
11 clinical trials registered, 8 recruiting. Interventions under study include drug therapy, other interventions, medical devices, and biologic therapy. Pipeline includes 3 PHASE2, 2 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05863234](https://clinicaltrials.gov/study/NCT05863234) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 12:59 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about aggressive NK-cell leukemia
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia |
PHASE1 |
Hiroshima University Hospital |
RECRUITING |
[NCT06716658](https://clinicaltrials.gov/study/NCT06716658) | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | PHASE2 | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
[NCT05475925](https://clinicaltrials.gov/study/NCT05475925) | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | PHASE1 | Dren Bio | RECRUITING |
[NCT01137643](https://clinicaltrials.gov/study/NCT01137643) | Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer | — | UNC Lineberger Comprehensive Cancer Center | RECRUITING |
[NCT04645199](https://clinicaltrials.gov/study/NCT04645199) | National Longitudinal Cohort of Hematological Diseases | — | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
56 publications have been identified in PubMed for aggressive NK-cell leukemia. Research spans Review / Meta-Analysis (27%), Case Report / Case Series (27%), and Basic Science / Preclinical (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 15 | 27% |
Patient case studies | 15 | 27% |
Laboratory research | 9 | 16% |
Disease patterns and progression | 6 | 11% |
Testing and diagnosis research | 5 | 9% |
Clinical study results | 4 | 7% |
New treatment approaches | 1 | 2% |
Gonzalez Mancera M (2026). [PMID: 42054237](https://pubmed.ncbi.nlm.nih.gov/42054237/). *Am J Clin Pathol*. [Review / Meta-Analysis]
Wang H (2026). [PMID: 42099645](https://pubmed.ncbi.nlm.nih.gov/42099645/). *Front Immunol*. [Case Report / Case Series]
Yuan CT (2026). [PMID: 41466159](https://pubmed.ncbi.nlm.nih.gov/41466159/). *The journal of pathology. Clinical research*. [Diagnostic / Biomarker]
Komori Y (2026). [PMID: 42128859](https://pubmed.ncbi.nlm.nih.gov/42128859/). *Rinsho Ketsueki*. [Case Report / Case Series]
Liu M (2026). [PMID: 42161665](https://pubmed.ncbi.nlm.nih.gov/42161665/). *Zhonghua Xue Ye Xue Za Zhi*. [Review / Meta-Analysis]
Ke J (2026). [PMID: 41196088](https://pubmed.ncbi.nlm.nih.gov/41196088/). *International journal of laboratory hematology*. [Case Report / Case Series]
Wilk AJ (2026). [PMID: 41786213](https://pubmed.ncbi.nlm.nih.gov/41786213/). *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. [Epidemiology / Natural History]
Filonenko K (2026). [PMID: 41906380](https://pubmed.ncbi.nlm.nih.gov/41906380/). *Asia-Pacific journal of clinical oncology*. [Review / Meta-Analysis]
Li C (2026). [PMID: 41308748](https://pubmed.ncbi.nlm.nih.gov/41308748/). *Laboratory investigation; a journal of technical methods and pathology*. [Basic Science / Preclinical]
Luniewski A (2026). [PMID: 41657941](https://pubmed.ncbi.nlm.nih.gov/41657941/). *Lymphatics*. [Case Report / Case Series]